Fig. 1: Structural and antigenic characterisation of bYFVs.
a Representative cryo-EM micrographs of purified bYFV17D, bYFVES504 and bYFVAsibi particles incubated at 4 °C prior to freezing. b Two-dimensional class averages of bYFV17D and bYFVES504 particles. The displayed class distribution is shown as a percentage of the total number of particles. Cryo-EM density map of bYFV17D (c) and bYFVES504 (d) with I3 symmetry applied. The maps are radially coloured according to the following: 0-150 Å red, 151-195 Å yellow, 196-210 Å green, 211-225 Å cyan, 226-240 Å blue Å. e IC50 values of recombinant hIgG1 anti-YFV or anti-flavivirus mAbs against bYFV17D, bYFVES504 and bYFVAsibi. Each symbol represents a technical replicate from three biological replicates (n = 6). f Serum neutralising titres of human YFV17D vaccinees (n = 14) against bYFV17D, bYFVES504 and bYFVAsibi. In both (e) and (f), neutralisation was determined via FRNTs on C6/36 (Aedes albopictus) cells. Lines indicate group medians. Significance was determined via Kruskal-Wallis tests with Dunn’s multiple comparisons test on GraphPad Prism 9.0. ****p < 0.0001, ***p ≤ 0.0002, **p ≤ 0.002, *p ≤ 0.03. For 2C9: p = 0.006 (ES504 vs. Asibi), 2A10G6: p = 0.040 (17D vs. ES504) and p = 0.002 (17D vs. Asibi), 6B6C−1: p = 0.034 (17D vs. ES504) and p = 0.002 (17D vs. Asibi), 864: p = 0.0015 (17D vs. ES504 and 17D vs. Asibi), human vaccinee sera: p = 0.0001 (17D vs ES504) and p = 0.046 (17D vs Asibi). LOD = limit of detection. Source data is provided as a Source Data file.
